Abstract
In our previous study on [Met5]-enkephalin analogues, [Met5]-enkephalin semicarbazide was found as a new enkephalin amide that produces antinociception even in ACE (Angiotensin Converting Enzyme) exposure in vivo. In the present work we examined the corresponding [Leu5]-enkephalin derivatives to confirm the influence of semicarbazide substitution. To prevent the enkephalins biodegradation animals were pretreated with a mixture of peptidase inhibitors. As assessed by tail-flick test no significant difference was detected between the produced antinociception by the [Leu5]-enkephalin derivatives. Based on our results both semicarbazide and ethylamide groups could preserve the provided analgesia after captopril (ACE inhibitor) omission from the peptidase inhibitors mixture. This work confirms that semicarbazide substitution on enkephalins yields ACE resistance antinociceptive peptides, nevertheless it may necessarily not enhance the peptides analgesic potencies.
References
Akahori K, Kosaka K, Jin XL, Arai Y, Yoshikawa M, Kobayashi H, Oka T (2008) Great increase in antinociceptive potency of [Leu 5]enkephalin after peptidase inhibition. J Pharmacol Sci 106:295–300
Arabanian A, Mohammadnejad M, Balalaie S (2010) A novel and efficient approach for the amidation of C-terminal peptides. J Iran Chem Soc 7:840–845
Boudinot E, Morin-Surun MP, Foutz AS, Fournié-Zaluski MC, Roques BP, Denavit-Saubié M (2001) Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration. Pain 90:7–13
Chen W, Song B, Lao L, Pérez OA, Kim W, Marvizón JCG (2007) Comparing analgesia and [mu]-opioid receptor internalization produced by intrathecal enkephalin: requirement for peptidase inhibition. Neuropharmacology 53:664–676
Chipkin RE, Morris DH, English MG, Rosamond JD, Stammer CH, York EJ, Stewart JM (1981) Potent tetrapeptide enkephalins. Life Sci 28:1517–1522
Corvol P, Williams TA, Soubrier F (1995) [18] Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol 248:283–305
D’Amour FE, Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79
Erdös E (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 16:363–370 Lewis K. Dahl memorial lecture
Erdos E, Skidgel R (1986) The unusual substrate specificity and the distribution of human angiotensin I converting enzyme. Hypertension 8(I):34–37
Ghoda K, Iwao K, Liu XF, Taniguchi T, Oka T (1995) The in vitro and in vivo resistance of synthetic enkephalin analogs to three enkephalin-hydrolyzing enzymes. Regul Pept 59:87–96
Gupta Y, Chugh A, Arora S, Seth S (1991) Modulation of morphine induced antinociception by intracerebroventricularly administered captopril. Indian J Exp Biol 29:543–545
Hiranuma T, Iwao K, Kitamura K, Matsumiya T, Oka T (1997) Almost complete protection from [Met5]-enkephalin-Arg6-Gly7-Leu8 (Met-enk-RGL) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon. J Pharmacol Exp Ther 281:769–274
Houard X, Williams TA, Michaud A, Dani P, Isaac RE, Shirras AD, Coates D, Corvol P (1998) The Drosophila melanogaster related angiotensin I converting enzymes Acer and Ance. Eur J Biochem 257:599–606
Kanai M, Takahashi S, Kosaka K, Iwao K, Kobayashi H, Oka T (2002) [Met5] enkephalin–Arg–Gly–Leu-induced antinociception is greatly increased by peptidase inhibitors. Eur J Pharmacol 453:53–58
Kedlaya D, Reynolds L, Waldman S (2002) Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 16:651–665
Kitamura K, Akahori K, Yano H, Iwao K, Oka T (2000) Effects of peptidase inhibitors on anti-nociceptive action of dynorphin-(1-8) in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 36:273–278
Lamango NS, Sajid M, Isaac RE (1996) The endopeptidase activity and the activation by Cl-of angiotensin-converting enzyme is evolutionarily conserved: purification and properties of an angiotensin-converting enzyme from the housefly, Musca domestica. Biochem J 314:639–646
Lantz I, Nyberg F, Terenius L (1991) Molecular heterogeneity of angiotensin converting enzyme in human cerebrospinal fluid. Biochem Int 23:941–948
Ling N, Guillemin R (1976) Morphinomimetic activity of synthetic fragments of beta-lipotropin and analogs. Proc Natl Acad Sci 73:3308–3310
Maldonado R, Feger J, Fournie-Zaluski M, Roques B (1990) Differences in physical dependence induced by selective [mu] or [delta] opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Brain Res 520:247–254
Malfroy B, Schwartz JC (1985) Comparison of dipeptidyl carboxypeptidase and endopeptidase activities in the three enkephalin-hydrolysing metallopeptidases. Biochem Biophys Res Commun 130:372–378
Noble F, Roques BP (2007) Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin Ther Target 11:145–159
Norman J, Autry W, Barbaz B (1985) Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain. Mol Pharmacol 28:521–526
Ortega-Alvaro A, Chover-Gonzalez AJ, Lai-Kuen R, Mico JA, Gibert-Rahola J, Fournié-Zaluski MC, Roques BP, Maldonado R (1998) Antinociception produced by the peptidase inhibitor, RB 101, in rats with adrenal medullary transplant into the spinal cord. Eur J Pharmacol 356:139–148
Paronis CA, Holtzman SG (1991) Increased analgesic potency of mu agonists after continuous naloxone infusion in rats. J Pharmacol Exp Ther 259:582–589
Rezaee Z, Arabanian SA, Balalaie S, Ahmadiani A, Khalaj L, Nasoohi S (2012) Antinociceptive effect of [Met5] enkephalin semicarbazide is not affected by dipeptidyl carboxypeptidase I. J Pept Sci 18:92–96
Rodriguez R, Reig F, Valencia G, Herrero J, Garcia Anton J (1986) Biological activity of Leu-enkephalin containing hydrophobic moieties. Neuropeptides 8:335–349
Schwartz JC, Malfroy B, De La Baume S (1981) Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase. Life Sci 29:1715–1740
Song B, Marvizón JCG (2003) Peptidases prevent μ-opioid receptor internalization in dorsal horn neurons by endogenously released opioids. J Neurosci 23:1847–1858
Taniguchi T, Fan XT, Kitamura K, Oka T (1998) Effects of peptidase inhibitors on the enkephalin-induced anti-nociception in rats. Jpn J Pharmacol 78:487–492
Tölle TR, Schadrack J, Castro-Lopes JM, Evan G, Roques BP, Zieglgänsberger W (1994) Effects of Kelatorphan and morphine before and after noxious stimulation on immediate-early gene expression in rat spinal cord neurons. Pain 56:103–112
Tóth F, Farkas J, Tóth G, Wollemann M, Borsodi A, Benyhe S (2003) Synthesis and binding characteristics of a novel enkephalin analogue, [< sup > 3 </sup > H] Tyr-d-Ala-Gly-Phe-d-Nle-Arg-Phe. Peptides 24:1433–1440
Watkins R, Vemulapalli S, Chiu P, Foster C, Smith E, Neustadt B, Haslanger M, Sybertz E (1993) Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor. Am J Hypertens 6:357–368
Yaksh TL, Rudy TA (1976) Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17:1031–1036
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rezaee, Z., Arabanian, A., Balalaie, S. et al. Semicarbazide Substitution Enhances Enkephalins Resistance to Ace Induced Hydrolysis. Int J Pept Res Ther 18, 305–309 (2012). https://doi.org/10.1007/s10989-012-9306-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-012-9306-z